De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Oleg GluzUlrike NitzCornelia Kolberg-LiedtkeAleix PratMatthias ChristgenSherko KuemmelMohammad Parsa MohammadianDaniel GebauerRonald KatesLaia ParéEva-Maria GrischkeHelmut ForstbauerMichael BraunMathias WarmJohn HackmannChristoph UleerBahriye AktaşClaudia SchumacherRachel WuerstleinMonika GräserEnrico PelzKatarzyna JóźwiakChristine Zu EulenburgHans Heinrich KreipeNadia Harbecknull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Short de-escalated neoadjuvant taxane/platinum-based combination therapy appears to be a promising strategy in early TNBC for using pCR rate as an early decision point for further therapy (de-) escalation together with node-negative status and high sTILs. See related commentary by Sharma, p. 4840.
Keyphrases
- neoadjuvant chemotherapy
- combination therapy
- lymph node
- locally advanced
- rectal cancer
- sentinel lymph node
- squamous cell carcinoma
- open label
- study protocol
- randomized controlled trial
- phase iii
- stem cells
- phase ii
- early stage
- decision making
- bone marrow
- metastatic breast cancer
- replacement therapy
- double blind
- chemotherapy induced
- placebo controlled